The Business Research Company’s report on the Corifact Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
#How have key drivers contributed to the rapid growth of the corifact market?
The increasing prevalence of bleeding disorders is expected to propel the growth of the corifact market going forward. Bleeding disorders are conditions that impair the blood’s ability to clot properly, leading to excessive or prolonged bleeding. The rise in bleeding disorders can be attributed to improved diagnosis, increased awareness, advances in genetic testing, as well as lifestyle changes and the prevalence of underlying conditions. Corifact treats bleeding disorders caused by factor XIII deficiency by replacing the missing clotting factor, helping form stable blood clots, and reducing excessive bleeding. For instance, in October 2023, according to a report published by the World Federation of Hemophilia Report, a Canada-based non-profit organization, in 2022, 427,685 individuals worldwide were diagnosed with bleeding disorders. This included 257,146 cases of hemophilia (208,957 of hemophilia A, 42,203 of hemophilia B, and 5,986 with an unspecified type), 100,505 cases of von Willebrand disease, and 70,034 cases of other bleeding disorders. Therefore, the increasing prevalence of bleeding disorders is driving the growth of the corifact market.
Access Your Free Sample of the Global Corifact Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=20024&type=smp
How has the corifact market size evolved, and what are the latest forecasts for its expansion?
The corifact market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to increased utilization of factor XIII concentrates, increased awareness, increased automation, demand for extended care delivery, and adoption of new plasma fractionation technologies.
The corifact market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to the increasing prevalence of bleeding disorders, increasing awareness and early diagnosis, increasing the number of surgical procedures, growing client base reliance, and increasing the half-life of factor VIII. Major trends in the forecast period include technological developments, advancements in the healthcare infrastructure, innovative approaches to developing recombinant therapies, advancements in biotechnology, and FDA approval of Corifact.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=20024&type=smp
Which major companies dominate the corifact market?
Major companies operating in the corifact market include CSL Behring
Which region dominates the corifact market, and what factors contribute to its leadership?
North America was the largest region in the corifact market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corifact market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/corifact-global-market-report
How is the corifact market segmented, and which segment holds the largest share?
The corifact market covered in this report is segmented –
1) By Product: Human-Derived Factor XIII, Recombinant Factor XII
2) By Therapeutic Applications: Routine Prophylactic Treatment, Peri-Operative Management
3) By Distribution Channels: Hospital Pharmacies, Specialty Pharmacies, Outpatient Clinics
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20024
What defines the structure and scope of the corifact market?
Corifact refers to a fibrinogen concentrate used in medical treatments to manage bleeding, particularly in patients with fibrinogen deficiency or low fibrinogen levels, which can occur in conditions such as trauma, surgery, or liver disease. Corifact helps to promote blood clotting by providing fibrinogen, a protein essential for the formation of blood clots.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
